Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu

Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT01994174
Recruitment Status : Recruiting
First Posted : November 25, 2013
Last Update Posted : June 5, 2020
Sponsor:
Information provided by (Responsible Party):
Vikas Gulati, MD, University of Nebraska

Tracking Information
First Submitted Date November 19, 2013
First Posted Date November 25, 2013
Last Update Posted Date June 5, 2020
Actual Study Start Date February 2014
Estimated Primary Completion Date February 2021   (Final data collection date for primary outcome measure)
Current Primary Outcome Measures
 (submitted: September 12, 2017)
Uveoscleral outflow changes [ Time Frame: 1-2 months ]
The uveoscleral outflow changes will be assess at baseline prior to any anti-VEGF treatment and after the 3rd intravitreal treatment has been done.
Original Primary Outcome Measures
 (submitted: November 19, 2013)
Uveoscleral outflow changes [ Time Frame: 3 months ]
The uveoscleral outflow changes will be assess at baseline prior to any anti-VEGF treatment and after the 3rd intravitreal treatment has been done.
Change History
Current Secondary Outcome Measures Not Provided
Original Secondary Outcome Measures Not Provided
Current Other Pre-specified Outcome Measures Not Provided
Original Other Pre-specified Outcome Measures Not Provided
 
Descriptive Information
Brief Title Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
Official Title Effect of Vascular Endothelial Growth Factor Blockers on Aqueous Humor Dynamics
Brief Summary The objective of this research is to determine the effects of anti-VEGF drugs (bevacizumab, ranibizumab or aflibercept) on aqueous humor dynamics (AHD) in patients with retinal vascular disease. The underlying hypothesis is that anti-VEGF drugs increase intraocular pressure (IOP) by increasing aqueous inflow, decreasing uveoscleral outflow or both. The specific aim is to evaluate the changes produced in AHD after 1 baseline and a subsequent 1 monthly injection of anti VEGF agents.
Detailed Description

Intravitreal injection of different anti-VEGF agents such as bevacizumab (Avastin, Genentech, Inc., South San Francisco, CA, USA) ranibizumab (Lucentis; Genentech, Inc., South San Francisco, CA, USA) and aflibercept (Eylea, Regeneron, Tarrytown, NY, USA) has been a widely common practice for treatment of choroidal neovascularization and retinal vascular diseases [1]. Several ocular and systemic adverse events have been reported with the use of anti-VEGF agents [7]. Elevation of intraocular pressure (IOP) is a serious ocular adverse event that may be associated with intravitreal injection of anti-VEGF agents. IOP elevation with anti-VEGF injection may have variable presentation ranging from acute transient post injection elevation to the development of persistent IOP elevation that mandates pressure lowering therapy[8].

Patients with previously existing glaucoma may have a higher rate of persistent IOP elevation associated with intravitreal injection of anti-VEGF agents. Good et al, reported the rate of persistent IOP elevation after intravitreal anti-VEGF to be 33% in glaucoma patients versus 3.1% in eyes without previous diagnosis of glaucoma [9]. Tseng et al, reported 25 eyes with sustained elevation of IOP after serial intravitreal injections of anti-VEGF agents (mean = 20injections). All the 25 eyes were normotensive prior to the study and 23 of them were not previously diagnosed with glaucoma[10].

Multicenter clinical trials that studied the intravitreal injection of anti-VEGF agents, such as MARINA and ANCHOR for ranibizumab, VISION for pegaptanib and PACORES for bevacizumab, did not show sustained IOP elevation with the intravitreal injection of the study agents [12-15]. However, a subgroup analysis of the data of MARINA and ANCHOR trials showed at least 6 mm Hg increase of IOP from baseline in 2.1% of eyes in MARINA trial and 3.6% of eyes in ANCHOR trial [16]. A retrospective chart review of 207 patients over a 6-months follow up period after serial intravitreal injections of anti-VEGF reported an IOP elevation greater than 5 mm Hg in 2 consecutive visits compared to baseline in 11.6% of the treated eyes versus 5.3% in control eyes [17].

The pathophysiology of the reported IOP elevation associated with intravitreal injection of anti-VEGF is unknown. Anti-VEGF compounds might increase aqueous humor inflow by the breakdown of the blood-aqueous barrier or reduce uveoscleral outflow by the ciliary body vasculature. These potential changes could translate into elevated IOP and glaucoma.

Study Type Observational [Patient Registry]
Study Design Observational Model: Cohort
Time Perspective: Prospective
Target Follow-Up Duration 4 Weeks
Biospecimen Not Provided
Sampling Method Probability Sample
Study Population Patients with established diagnosis of retinal vascular diseases (diabetic macular edema, neovascular macular degeneration, presumed ocular histoplasmosis syndrome, high myopia) who require intravitreal injection of anti-VEGF drugs such as bevacizumab, ranibizumab or aflibercept and are likely to need three monthly doses.
Condition Macular Disease
Intervention Not Provided
Study Groups/Cohorts Not Provided
Publications * Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Recruitment Information
Recruitment Status Recruiting
Estimated Enrollment
 (submitted: November 19, 2013)
30
Original Estimated Enrollment Same as current
Estimated Study Completion Date February 2021
Estimated Primary Completion Date February 2021   (Final data collection date for primary outcome measure)
Eligibility Criteria

Inclusion Criteria:

  • Subjects must be at least 19 years of age and older
  • Ability to give informed consent and attend the study visits
  • Patients with established diagnosis of retinal vascular diseases (diabetic macular edema, neovascular macular degeneration,presumed ocular histoplasmosis syndrome, high myopia) who require intravitreal injection of anti-VEGF drugs such as bevacizumab,ranibizumab or aflibercept and are likely to need three monthly doses.
  • Patients who have not received intravitreal injections within 3 months of study entry
  • No previous established diagnosis of glaucoma and consequently no previous history of Argon Laser Trabeculoplasty (ALT) or Selective Laser Trabeculoplasty (SLT).
  • No previous history of ocular surgery
  • Patients who are not planning on and are unlikely to require an elective ocular surgical or laser procedure within the study duration
  • Open angle of the anterior chamber on clinical examination
  • Ability to cooperate for aqueous humor dynamic studies
  • Contact lenses removed prior to topical fluorescein instillation, and not used until the end of each fluorophotometry session
  • Able to participate on site over the multi-visit study period

Exclusion Criteria:

  • Age less than 18 years of age
  • Women who are pregnant or nursing
  • Ocular hypertension or glaucoma
  • Narrow angle with complete or partial closure (gonioscopy angle <2)
  • Any previous surgical or laser procedures
  • Secondary glaucoma including pigmentary, exfoliative, uveitic and traumatic glaucomas
  • Any active neovascularization of the iris, angle, disc or retina
  • Diagnosis of retinal arterial or vein occlusion
  • Chronic or recurrent inflammatory eye disease
  • Ocular trauma within the past 6 months
  • Ocular infection or ocular inflammation in the past 2 months
  • Any abnormality preventing reliable fluorophotometry of either eye,such as corneal scarring or severe dry eye that results in punctuate fluorescein staining of the cornea
  • Intraocular surgery within 6 months
  • Serious hypersensitivity to any components of the study medications or risk from treatment with glaucoma medications, such as severe asthma or emphysema.
  • Use of any glucocorticoid by any route. Subject must be washed out of the glucocorticoid for at least 2 weeks before study entry.
Sex/Gender
Sexes Eligible for Study: All
Ages 19 Years and older   (Adult, Older Adult)
Accepts Healthy Volunteers No
Contacts
Contact: Vikas Gulati, MD 402-559-4276 vgulati@unmc.edu
Contact: Kristi Miller 402-559-1853 kristi.miller@unmc.edu
Listed Location Countries United States
Removed Location Countries  
 
Administrative Information
NCT Number NCT01994174
Other Study ID Numbers 583-13-FB
Has Data Monitoring Committee No
U.S. FDA-regulated Product Not Provided
IPD Sharing Statement Not Provided
Responsible Party Vikas Gulati, MD, University of Nebraska
Study Sponsor University of Nebraska
Collaborators Not Provided
Investigators
Principal Investigator: Vikas Gulati, MD UNMC Department of Ophthalmology and Visual Sciences
PRS Account University of Nebraska
Verification Date June 2020